483 related articles for article (PubMed ID: 32945172)
21. A Review of Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer.
Heitz N; Greer SC; Halford Z
Ann Pharmacother; 2023 May; 57(5):585-596. PubMed ID: 35962528
[TBL] [Abstract][Full Text] [Related]
22. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA; Sonpavde GP; Kwak L; Regan MM; Gao X; Hvidsten H; Mantia CM; Wei XX; Berchuck JE; Berg SA; Ravi PK; Michaelson MD; Choueiri TK; Bellmunt J
Ann Oncol; 2024 Jan; 35(1):91-97. PubMed ID: 37871703
[TBL] [Abstract][Full Text] [Related]
23. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
[TBL] [Abstract][Full Text] [Related]
24. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
[TBL] [Abstract][Full Text] [Related]
25. Enfortumab-vedotin use for urothelial carcinoma in two patients on hemodialysis.
Khosla H; Bhatt S; Wang MJ; Gignac G; Mittal K; Patel J
J Oncol Pharm Pract; 2024 Jul; 30(5):941-944. PubMed ID: 38470473
[TBL] [Abstract][Full Text] [Related]
26. Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
Fahey CC; Nebhan CA; York S; Davis NB; Hurley PJ; Gordetsky JB; Schaffer KR
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003302
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
28. An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
Ren Y; Liu T; Li S; Ma X; Xia L; Wang P; Guo Q; Yao Y; Hou X; Sheng X; Zhu H; Yang Z
Int J Pharm; 2024 Feb; 651():123756. PubMed ID: 38160990
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
30. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
[TBL] [Abstract][Full Text] [Related]
31. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.
Chou J; Trepka K; Sjöström M; Egusa EA; Chu CE; Zhu J; Chan E; Gibb EA; Badura ML; Contreras-Sanz A; Stohr BA; Meng MV; Pruthi RS; Lotan Y; Black PC; Porten SP; Koshkin VS; Friedlander TW; Feng FY
Eur Urol Oncol; 2022 Dec; 5(6):714-718. PubMed ID: 35216942
[TBL] [Abstract][Full Text] [Related]
32. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
[TBL] [Abstract][Full Text] [Related]
33. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
[TBL] [Abstract][Full Text] [Related]
34. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
35. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
Azizi A; Houshyar R; Mar N
J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
[TBL] [Abstract][Full Text] [Related]
36. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
37. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Heath EI; Rosenberg JE
Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract][Full Text] [Related]
39. Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin.
Hanna KS
J Adv Pract Oncol; 2020; 11(4):412-417. PubMed ID: 33604101
[TBL] [Abstract][Full Text] [Related]
40. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
Maiorano BA; Catalano M; Maiello E; Roviello G
Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]